Cite
Chemotherapy/Pembrolizumab Improves pCR in Key ER+ Breast Cancer Subgroups.
MLA
Rosa, Kristi. “Chemotherapy/Pembrolizumab Improves PCR in Key ER+ Breast Cancer Subgroups.” Targeted Therapies in Oncology, vol. 13, no. 2, Feb. 2024, pp. 33–35. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=175884344&authtype=sso&custid=ns315887.
APA
Rosa, K. (2024). Chemotherapy/Pembrolizumab Improves pCR in Key ER+ Breast Cancer Subgroups. Targeted Therapies in Oncology, 13(2), 33–35.
Chicago
Rosa, Kristi. 2024. “Chemotherapy/Pembrolizumab Improves PCR in Key ER+ Breast Cancer Subgroups.” Targeted Therapies in Oncology 13 (2): 33–35. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=175884344&authtype=sso&custid=ns315887.